机构名称：
¥ 1.0
结果：这项荟萃分析涉及20个RCT，涉及7,832名参与者。The overall analysis demonstrated that maintenance therapy with PARP inhibitors led to signi fi cant improvements in PFS (HR: 0.398, 95% CI = 0.339 – 0.467, 95% PI = 0.219 – 0.724), OS (HR: 0.677, 95% CI = 0.582 – 0.788, 95% PI = 0.546 – 0.839), CFI (HR: 0.417, 95% CI = 0.368 – 0.472, 95% PI = 0.265 – 0.627), TFST (HR: 0.441, 95% CI = 0.391 – 0.498, 95% PI = 0.308 – 0.632), and TSST (HR: 0.574, 95% CI = 0.507 – 0.649,与安慰剂相比，95％PI = 0.488 - 0.674）。亚组分析进一步表明，无论同源重组状态如何，PARP抑制剂维持治疗显着改善了PFS（所有P <0.05）。但是，任何等级的风险（RR = 1.046，95％CI = 1.032 - 1.059，95％PI = 1.028 - 1.055）和≥3级茶（RR = 2.931，95％CI = 2.641 - 2.641 - 3.253，95％PI = 2.253，95％PI = 2.128 –3.792）。
PARP抑制剂维持疗法的功效和安全性...
主要关键词
相关文件推荐
